| Open Document File Size: 784,91 KBShare Result on Facebook
City Cambridge / Leeds / London / / Company 3Hammersmith Medicines Research Ltd. / AEs / Jared Gollob1 Alnylam Pharmaceuticals Inc. / Dose Group / / Country United States / United Kingdom / / Event FDA Phase / / MedicalCondition congestive heart failure / cardiomyopathy / Headache / SAD / Familial Amyloidotic Cardiomyopathy / hereditary form / Diastolic dysfunction / erythema / multisystem disease / TTR amyloidosis / pain / Local bruise / Transthyretin-mediated amyloidosis / heart failure / Transthyretin (TTR) cardiac amyloidosis / transient erythema / inflammation / / MedicalTreatment liver transplant / Heart transplant / / Organization 2Covance Clinical Research Unit / European Union / / Person Tracy Zimmermann / / Product SC / R2 / Vitamin A / V122I / FAC / / Region Caribbean / / Technology pharmacokinetics / siRNA / transplantation / pharmacodynamics / /
SocialTag |
Phase I First-in-Human Trial of ALN-TTRsc, A Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC) Tracy Zimmermann,1 Verena Karsten,1 Jamie Harrop,1 Amy Chan,1 Joseph Chiesa,2